Barclays maintains Iovance Biotherapeutics at Overweight, raises price target to $19 from $18
Barclays raised its price target for Iovance Biotherapeutics to $19 from $18, maintaining an Overweight rating. This implies a 145.5% upside from the Nov 5 close of $7.74. Recent analyst price targets for the company range from $8 to $18.
How this was made

The 30-second read
Why it matters
Analyst target increase suggests potential upside but lacks new operational catalysts.
Market read
Minor catalyst for IOV; limited broader market impact.
What to watch
No new clinical data; price move may be speculative.
Background
Iovance Biotherapeutics is a small‑cap biotech focused on cell therapies.
Market effects
May lift sentiment in the biotech sector.
Limited to US biotech investors.
Low
Counterpoint
Target raise could be premature if upcoming trial data disappoint.
Key entities
- AnalystBarclays
Raised price target to $19.



